Chicken Egg Yolk-IgY: Passive Immunization Promising Targeted Therapy of COVID-19 Pandemic | ||||
Journal of Applied Veterinary Sciences | ||||
Article 9, Volume 6, Issue 2, April 2021, Page 67-91 PDF (1.05 MB) | ||||
Document Type: Review Article | ||||
DOI: 10.21608/javs.2021.164324 | ||||
View on SCiNiTO | ||||
Authors | ||||
Ibrahim Rehan 1; Asmaa Elnagar 2 | ||||
1Department of Husbandry and Development of Animal Wealth, Faculty of Veterinary Medicine, Menofia University, Shebin Alkom, Menofia, Egypt. | ||||
2Department of Biochemistry, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt. | ||||
Abstract | ||||
The world is threatened by the lethal effects of Coronaviruses (CoVs) that associated with major respiratory disorders. The CoVs are large, enveloped, positive-stranded RNA and therefore, it is considered a complicated virus structure. The spike (S) is the major protein that exists in CoV’s structure regulates the viral access to the host using angiotensin-converting enzyme 2 (ACE2) receptor for both severe acute respiratory syndrome Coronaviruses-2 (SARS-CoV-2) and/or SARS-CoV initiates the animal/human disease and elevated immune responses. The receptor binding domain (RBD) in the S-proteins is essential for the CoVs-gene sequences; however the literature discussed CoV S-protein in relation to receptor-binding is little. Therefore, finding a natural antiviral to limit the spreading of CoVs is important. Herein, Immunoglobulin (Ig) Y is considered a kind of passive immunizations, represents 60% of the egg-yolk and can preventing many infectious diseases due to the particularities of IgY-molecule shape functional bioactivity to combat the pathogens. Comparing IgY to other Ig(s) antibodies, it makes the minimal animal stress, produces the lowest responses to mammalian factors. Besides, IgY is the most cost-effective extraction using the precipitation which is efficient protocol produce about (95% purity) of antibodies. We reported that IgY has a killing power to bacterial infections in broilers which beneficial to produce hygienic meat. Also, IgY-technology has a global application for treatment of viral infections and cancers. Interestingly, the anti-SARS CoV-2 single-chain fragments variable (scFv) IgY-antibodies can separate the virus from the host cell ACE2-and RBD-receptors. The expressed scFv-antibody can be assigned to be a specific-antigen binding for the potential neutralization which make a better understanding of the host-cycle range of SARS-CoV2 to adapt the ACE2 for the SARS-CoV-2 infection. Therefore, we concluded in this review that the IgY is promising to be a therapeutic target of a novel Coronaviruses disease-19 (COVID-19) pandemic. | ||||
Keywords | ||||
COVID-19; Egg-yolk; Immunoglobulin Y; Passive immunity; Therapy | ||||
References | ||||
ABBAS A.T., EL‑KAFRAWY S.A., SOHRAB S.S., AZHAR E.I.A. 2019. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections. Hum Vaccin Immunother 15(1): 264‑275. doi: 10.1080/21645515.2018.1514224.
AJUFO E., RADER D.J. 2016. Recent advances in the pharmacological management of hypercholesterolaemia, Lancet Diab. Endocrinol 4(5): 436–446. doi: 10.1016/S2213-8587(16)00074-7.
AKITA E., JANG C., KITTS D., NAKAI S. 1999. Evaluation of allergenicity of egg yolk immunoglobulin Y and other egg proteins by passive cutaneous anaphylaxis. Food Agric Immunol 11(2): 191‑201. doi: 10.1080/09540109999861.
ALLEN T.M. 2002. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10): 750–763. doi: 10.1038/nrc903.
ALMAZÁN F., SOLA I., ZUIGA S., MARQUEZ-JURADO S., MORALES L., BECARES M., ENJUANES L. 2014. Coronavirus reverse genetic systems: Infectious clones and replicons. Virus Res 189: 262–270. doi:10.1016/j.virusres.2014.05.026.
ALUSTIZA F., BELLINGERI R., PICCO N., MOTTA C., GROSSO M.C., BARBERO C.A., ACEVEDO D.F., VIVAS A. 2016. IgY against enterotoxigenic Escherichia coli administered by hydrogel-carbon nanotubes composites to prevent neonatal diarrhoea in ex-perimentally challenged piglets. Vaccine 34(28): 3291–3297. doi: 10.1016/j.vaccine.2016.05.004.
AMIRIJAVID S., ENTEZARI M., MOVAFAGH A., HASHEMI M., MOSAVI-JARAHI A., DEHGHANI H. 2016. Apoptotic killing of breast cancer cells by IgYs produced against a small 21 aminoacid epitope of the human TRAIL-2 receptor. Asian Pacific J Cancer Prev 17(3): 293–297. doi: 10.7314/apjcp.2016.17.s3.293.
AMRO W.A., AL‑QAISI W., AL‑RAZEM F. 2018. Production and purification of IgY antibodies from chicken egg yolk. J Genet Eng Biotechnol 16(1): 99‑103. doi: 10.1016/j.jgeb.2017.10.003.
ANCUCEANU R., NEAGU M. 2016. Immune based therapy for melanoma. Indian J Med Res 143(2): 135‑144. doi: 10.4103/0971-5916.180197.
ANDERSEN K.G., RAMBAUT A., LIPKIN W.I., HOLMES E.C., GARRY R.F. 2020. The proximal origin of SARS-CoV-2. Nat Med 26(4): 450-452. doi: 10.1038/s41591-020-0820-9.
BACHTIAR E.W., AFDHAL A., MEIDYAWATI R., SOEJOEDONO R.D., POERWANINGSIH E. 2020. Effect of topical anti-Streptococcus mutans IgY gel on quantity of S. mutans on rats’ tooth surface, Acta Microbiol Immunol Hung 2016; 63(2): 159–169, https:// International Immunopharmacol 81: 106269. doi: 10.1556/030.63.2016.2.2.
BAE J.S., PARK J.M., LEE J., OH B.C., JANG S.H., BIN LEE Y., HAN Y.M., OCK C.Y., CHA J.Y., HAHM K.B. 2017. Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice. Metabolism 66: 32–44. doi: 10.1016/j.metabol.2016.10.002.
BAGATINI M.D., MACHADO CARDOSO A., DOS SANTOS A., BARBOSA CARVALHO F. 2017. Immune system and chronic diseases. J Immunol Res 1–3. doi: 10. 1155/2017/4284327.
BALLS M. 2010. The principles of humane experimental technique: Timeless insights and unheeded warning, ALTEX 27(2): 19–23.
doi: 10.14573/altex.2010.2.144.
BÁNYAI K., ESTES M.K., MARTELLA V., PARASHAR U.D. 2018. Viral gastroenteritis, Lancet 392(10142): 175–186. doi: 10.1016/S0140-6736(18)31128-0.
BARANIUK C. 2020. Scientists scan for weaknesses in the SARS-CoV-2 spike protein: The Scientist, https://www.the-scientist.com/news-opinion/scientists-scan-for-weaknesses-in-the-sars-cov-2-spike-protein-67404.
BAXTER D. 2007. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond) 57(8):552‑556. doi: 10.1093/occmed/kqm110.
BAZAN J., CAŁKOSIŃSKI I., GAMIAN A. 2012. Phage display—a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Human Vacc Immunotherap 8(12):1817–1828. doi: 10.4161/hv.21703.
BOONE D. 2014. Uses of a gastrokine protein, PCT patent WO2014099400, https://patents.google.com/patent/WO2014099400A2/en?oq=WO2014099400.
BREIDENSTEIN E.B.M., DE LA FUENTE-NÚÑEZ C., HANCOCK R.E.W. 2011.Pseudomonas aeruginosa: All roads lead to resistance. Trends Microbiol. 19(8): 419–426. doi: 10.1016/j.tim.2011.04.005.
BRELJE T.C., WESSENDORF M.W., SORENSON R.L. 2002. Multicolor laser scanning confocal immunofluorescence microscopy: Practical application and limitations. Methods Cell Biol 70: 165–244. doi: 10.1016/s0091-679x(02)70006-x.
CARLANDER D. AVIAN IGY ANTIBODY. 2002. In vitro and In Vivo, Uppsala University, http://www.diva-portal.,org/smash/record.jsf?pid=diva2%3A161296&dswid=309.
CARLANDER D., LARSSON A. 2001. Avian antibodies can eliminate interference due to complement activation in ELISA, Ups J Med Sci 106(3): 189–195. doi: 10.3109/2000-1967-145.
CARLANDER D., STÅLBERG J., LARSSON A. 1999. Chicken antibodies: A clinical chemistry perspective. Ups J Med Sci 104(3): 179‑189. doi: 10.3109/03009739909178961.
CASADEVALL A., DADACHOVA E., PIROFSKI L.A. 2004. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2(9): 695‑703. doi: 10.1038/nrmicro974.
CASADEVALL A., SCHARFF M.D. 1995. Return to the past: The case for antibody‑based therapies in infectious diseases. Clin Infect Dis 21(1):150-160. doi: 10.1093/clinids/21.1.150.
CHACANA P., TERZOLO H., GUTIÉRREZ CALZADO E., SCHADE R. 2004. Tecnología lgY o aplicaciones de los anticuerpos de yema de huevo de gallina, Rev Med et (Bogota) 85(5): 179–189. https://www.researchgate.net/publication/280741443_Tecnologia_IgY_o_aplicaciones_de_los_anticuerpos_de_yema_de_huevo_de_gallina.
CHALGHOUMI R., MARCQ C., THÉWIS A., PORTETELLE D., BECKERS Y. 2009. Effects of feed supplementation with specific hen egg yolk antibody (immunoglobin Y) on Salmonella species cecal colonization and growth performances of challenged broiler chickens. Poult Sci 88(10): 2081‑2092. doi: 10.3382/ps.2009-00173.
CHAPMAN A., EL MIEDANY Y. 2017. Psoriasis, Comorbidity Rheum. Dis 53: 1–124. doi: 10.1007/978-3-319-59963-2_4.
CHAVEZ-CORTEZ E.G., VARGAS FELIX G., RANGEL LÓPEZ E., SOTELO J., MARTÍNEZ-CANSECO C., PÉREZ-DE LA CRUZ V., PINEDA B. 2019. Production and evaluation of an avian IgY immunotoxin against CD133+ for treatment of carcinogenic stem Cells in malignant glioma: IgY immunotoxin for the treatment of glioblastoma. J Oncol 1–15. doi: 10.1155/2019/2563092.
CHEN D. 2012. Compositions and methods for treating hepatitis virus infection, PCT patent WO2012016429, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230139/.
CHEN H., HE F., SUN Y., LUO Y., QIU H.J., ZHANG X.Y., SUTTON B.J. 2015. Generation and characterization of chicken-sourced single-chain variable fragments (scFvs) against porcine interferon-gamma (pIFN-γ). J Immunoassay Immunochem 36(1): 27–44. doi: 10.1080/15321819.2014.892511.
CHENG V.C., LAU S.K., WOO P.C., YUEN K.Y. 2007. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 20(4): 660 ‑694. doi: 10.1128/CMR.00023-07.
CHORARIA A., SOMASUNDARAM R., GAUTAM M., RAMANATHAN M., PARAY B.A., AL-SADOON M.K., MICHAEL A. 2020. Experimental antivenoms from chickens and rabbits and their comparison with commercially available equine antivenom against the venoms of Daboia russelii and Echis carinatus snakes. Toxin Rev 1–12. doi: 10.1080/15569543.2020.1756858.
CONROY P.J, LAW R.H.P., GILGUNN S., HEARTY S., CARADOC-DAVIES T.T., LLOYD G.J., O'KENNEDY R.J., WHISSTOCK J.C. 2014. Reconciling the structural attributes of avian antibodies. J Biol Chem 289(22):15384–15392. doi: 10.1074/jbc.M114.562470.
CONSTANTIN C., VIORICA C., SIMA L., MIHAI L., PATRASCU I. 2017. Manufacture and use of personalized hyperimmune egg in psoriasis treatment, PCT patent WO2017065626, https://patents.google.com/patent/WO2017065626A1/en?oq=WO2017065626.
CORTI D., PASSINI N., LANZAVECCHIA A., ZAMBON M. 2016. Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. J Infect Public Health 9(3): 231‑235. doi: 10.1016/j.jiph.2016.04.003.
CUI J., LI F., SHI Z-L. 2019. Origin and evolution of pathogenic coronaviruse. Nat Rev Microbiol 17(3):181–192. doi: 10.1038/s41579-018-0118-9.
CZAKÓ R., ATMAR R.L., OPEKUN A.R., GILGER M.A., GRAHAM D.Y., ESTES M.K. 2012. Serum hemagglutination inhibition activity correlates with protection from gastro-enteritis in persons infected with Norwalk virus, Clin. Vaccine Immunol 19(2): 284–287. doi: 10.1128/CVI.05592-11.
DA SILVA M.C., SCHAEFER R., GAVA D., SOUZA C.K., DA SILVA VAZ I.JR., BASTOS A.P., VENANCIO E.J. 2018. Production and application of anti-nucleoprotein IgY antibodies for influenza A virus detection in swine. J Immunol Methods 461: 100‑105. doi: 10.1016/j.jim.2018.06.023.
DAI Y.-C., JIANG X. 2014. IgY from Norovirus P particles and their derivatives, PCT pa-tent WO2014011853, https://patents.google.com/patent/WO2014011853A3/en.
DAI Y-C., WANG Y-Y., ZHANG X-F., TAN M., XIA M., WU X-B., JIANG X., NIE J. 2012. Evaluation of anti-norovirus IgY from egg yolk of chickens immunized with nor-ovirus P particles. J Virol Methods 186(1-2): 126–131. doi: 10. 1016/j.jviromet.2012.07.002.
DAI Y-C., ZHANG X-F., TAN M., HUANG P., LEI W., FANG H., ZHONG W., JIANG X. 2013. A dual chicken IgY against rotavirus and norovirus. Antiviral Res 97(3): 293–300. doi: 10.1016/j.jacc.2007.01.076.White.
DAUGHERTY P.S. 2007. Protein engineering with bacterial display. Curr Opin Struct Biol 17(4): 474–480. doi: 10.1016/j.sbi.2007.07.004.
DAVIES J. 2002. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistance. Paediatr Respir Rev 3(2): 128–134. doi: 10.1016/S1526.
DEROCQ J-M., CASELLAS P., LAURENT G., RAVEL S., VIDAL H., JANSEN F. 1988. Comparison of the cytotoxic potency of T101 Fab, F (ab’) 2 and whole IgG immunotoxins. J Immunol 141(8): 2837–2843. https://europepmc.org/article/med/3262669.
DOCEA A.O., TSATSAKIS A., ALBULESCU D., CRISTEA O., ZLATIAN O., VINCETI M., MOSCHOS S.A., TSOUKALAS D., GOUMENOU M., DRAKOULIS N., DUMANOV J.M., VICTOR A. TUTELYAN VA, ONISCHENKO GG, ASCHNER M, SPANDIDOS DA, CALINA D. 2020. New threat from an old enemy: Re-emergence of coronavirus (Review). Int J Mol Med 45(6): 1631‑1643. doi: 10.3892/ijmm.2020.4555.
DROSTEN C., GÜNTHER S., PREISER W., VAN DER WERF S., BRODT H.R., BECKER S., RABENAU H., PANNING M., KOLESNIKOVA L., FOUCHIER R.A.M., BERGER A., BURGUIÈRE A-M., CINATL J., EICKMANN M., ESCRIOU N., GRYWNA K., KRAMME S., MANUGUERRA J-C., MÜLLER S., RICKERTS V., STÜRMER M., VIETH S., KLENK H-D., OSTERHAUS A.D.M.E., SCHMITZ H., DOERR H.W. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20): 1967‑1976. doi: 10.1056/NEJMoa030747.
EISFELD A.J., NEUMANN G., KAWAOKA Y. 2015. At the centre: Influenza A virus ribonucleoproteins. Nat Rev Microbiol 13(1): 28‑41. doi: 10.1038/nrmicro3367.
ELMS P. 2016. Advantages of multidimensional (Multi-D) chromatography using the NGC™ chromatography system over traditional sequential chromatography. Bulletin 6694. Bio -Rad Laboratories, Inc., Hercules, CA, https://www.biocompare.com/Bench-Tips/185013-Advantages-of-Multidimensional-Multi-D-Chromatography-what-s-it-all-about/.
ENJUANES L., ALMAZAN F., SOLA I., ZUNIGA S. 2006. Biochemical aspects of coronavirus replication and virus-host interaction. Annu Rev Microbiol60: 211–30. doi: 10.1146/annurev.micro.60.080805.142157.
ESMAILNEJAD A., ABDI‑HACHESOO B., HOSSEINI NASAB E., SHAKOORI M. 2019. Production, purification, and evaluation of quail immunoglobulin Y against Salmonella typhimurium and Salmonella enteritidis. Mol Immunol 107: 79‑83. doi: 10.1016/j.molimm.2019.01.012.
EUROPEAN MEDICINES AGENCY, EU/3/08/564. 2009. Public summary of positive opinion for orphan designation of avian polyclonal IgY antibody against Pseudomonas aeruginosa for the treatment of cystic fibrosis. https://www.ema.europa.eu/ documents/orphan-designation/eu/3/08/564-public-summary-positive-opinion-orphan-designation-avian-polyclonal-igy-antibody-against_en.pdf, (accessed 16 Jul 2019) .
FINLAY W.J.J., DEVORE N.C., DOBROVOLSKAIA E.N., GAM A., GOODYEAR C.S., SLATER J.E. 2005. Exploiting the avian immunoglobulin system to simplify the generation of recombinant antibodies to allergenic proteins. Clin Exp Allergy 35(8): 1040–1048. doi: 10.1111/j.1365-2222.2005.02307.
FU C.Y., HUANG H., WANG X.M., LIU Y.G., WANG Z.G., CUI S.J., GAO H.L., LI Z., LI J.P., KONG X.G. 2006. Preparation and evaluation of anti‑SARS coronavirus IgY from yolks of immunized SPF chickens. J Virol Methods 133(1): 112‑115. doi: 10.1016/j.jviromet.2005.10.027.
GAENSBAUER J.T., MELGAR M.A., CALVIMONTES D.M., LAMB M.M., ASTURIAS E.J., CONTRERAS-ROLDAN I.L., DOMINGUEZ S.R., ROBINSON C.C., BERMAN S. 2017. Efficacy of a bovine colostrum and egg-based intervention in acute childhood diarrhoea in Guatemala: a randomised, double-blind, placebo-controlled trial., BMJ Glob Heal 2(4): 1–12. doi: 10.1136/bmjgh-2017-000452.
GAO Y., YAN L., HUANG Y., LIU F., ZHAO Y., CAO L., WANG T., SUN Q., MING Z., ZHANG L., GE J., ZHENG L., ZHANG Y., WANG H., ZHU Y., ZHU C., HU T., HUA T., ZHANG B., YANG X., LI J., YANG H., LIU Z., XU W., GUDDAT L.W., WANG Q., LOU Z., RAO Z. 2020. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Sci 368(6492): 779-782. doi: 10.1126/science.abb7498.
GASSMANN M., THÖMMES P., WEISER T., HÜBSCHER U. 1990. Efficient production of chicken egg yolk antibodies against a conserved mammalian protein. FASEB 4(8): 2528‑2532. doi: 10.1096/fasebj.4.8.1970792.
GAVI. 2020. The Vaccine Alliance: The latest in the COVID-19 vaccine race. https://www.gavi.org/vaccineswork/covid‑19‑vaccine‑race. Accessed March 24, https://www.gavi.org/vaccineswork/covid19.
GE Y., SUN S. 2020. Estimation of coronavirus disease case‑fatality risk in real time. Emerg Infect Dis: Apr 21, 2020; 26(8), (Epub ahead of print). doi: 10.3201/eid2608.201096.
GILGUNN S., MILLÁN MARTÍN S., WORMALD M.R., ZAPATERO‑RODRÍGUEZ J., CONROY P.J., O'KENNEDY R.J., RUDD P.M., SALDOVA R., MONDELLI M.U. 2016. Comprehensive N‑Glycan profiling of avian immunoglobulin Y. PLoS One 11(7): e0159859. doi: 10.1371/journal.,pone.0159859.
GOEPP J.G.K. 2018. Systems and methods for altering microbiome to reduce disease risk and manifestations of disease, PCT patent WO2018026604, https://patents.google.com/patent/WO2018026604A1/en?oq=WO2018026604.
GRAHAM B.S., AMBROSINO D.M. 2015. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS 10(3): 129‑134. doi: 10.1097/COH.0000000000000154.
GREEN S.J., VENKATRAMANAN R., NAQIB A. 2015. Deconstructing the polymerase chain reaction: understanding and correcting bias associated with primer degeneracies and primer-template mismatches. PloS one 10(5): e0128122. doi: 10.1371/journal.,pone.0128122.
GRUBER F.P., HARTUNG T. 2004. Alternatives to animal experimentation in basic research, ALTEX 21(1): 1–31. https://pubmed.ncbi.nlm.nih.gov/15586255/.
GUIMARÃES M.C.C., AMARAL L.G., RANGEL L.B.A., SILVA I.V., MATTA C.G.F., DE MATTA M.F.R. 2009. Growth inhibition of Staphylococcus aureus by chicken egg yolk anti-bodies. Arch Immunol Ther Exp (Warsz) 57(5): 377–382. doi: 10.1007/s00005-009-0041-x.
HAMAL K.R., BURGESS S.C., PEVZNER I.Y., ERF G.F. 2006. Maternal antibody transfer from dams to their egg yolks, egg whites, and chicks in meat lines of chickens. Poult Sci 85(8): 1364‑1372. doi: 10.1093/ps/85.8.1364.
HAN Y., KRÁL P. 2020. Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano 14(4): 5143-5147. doi: 10.1021/acsnano.0c02857.
HATTA H., TSUDA K., AKACHI S., KIM M., YAMAMOTO T. 1993. Productivity and Some Properties of Egg Yolk Antibody (IgY) against human rotavirus compared with rabbit IgG. Biosci Biotechnol Biochem 57(3): 450–454. doi: 10.1271/bbb.57.450.
HATTA H., TSUDA K., AKACHI S., KIM M., YAMAMOTO T., EBINA T. 1993. Oral passive im-munization effect of anti-human rotavirus IgY and its behavior against proteolytic enzymes. Biosci Biotechnol Biochem 57(7): 1077–1081. doi: 10.1271/bbb.57.1077.
HE J., HU J., THIRUMALAI D., SCHADE R., DU E., ZHANG X-Y. 2016. Development of Indirect Competitive ELISA Using Egg Yolk-Derived Immunoglobulin (IgY) for the Detection of Gentamicin Residues. J Environ Sci Health B 51(1): 8–13. doi: 10.1080/03601234.2015.1080479.
HELLESTAD E.M., BISHOP J.W., PICCIONE M.L., COOK M.E., HELVIG C., BOBECK E.A., SAND J.M., PETKOVICH M. 2015. Oral peptide specific egg antibody to intestinal sodium-dependent phosphate co-transporter-2b is effective at altering phosphate transport in vitro and in vivo. Poult Sci 94(6): 1128–1137. doi: 10.3382/ ps/pev085.
HELMENSTINE A.M. 2019. An introduction to active immunity and passive immunity. ThoughtCo, https://www.thoughtco. com/active-immunity-and-passive-immunity-4134137. Accessed April 29, 2020.
HIROSE M., ANDO T., RAHMAN S., UMEDA K., KODAMA Y., NGUYEN S.V., GOTO T., SHIMADA M., NAGAOKA S. 2013. Anti-obesity activity of hen egg anti-lipase im-munoglobulin yolk, a novel pancreatic lipase inhibitor. Nutr Metab 10(1): 1–6. doi: 10.1186/1743-7075-10-70.
HOF D., HOEKE M.O., RAATS J.M.H. 2008. Multiple-antigen immunization of chickens facilitates the generation of recombinant antibodies to autoantigens. Clin Exp Immunol 151(2): 367–377 doi: 10.1111/j.1365-2249.2007. 03569.x.
HONDA K., LITTMAN D.R. 2016. The microbiota in adaptive immune homeostasis and disease, Nature 535: 75–84. doi: 10.1038/nature18848.
HONG K.S., KI M.R., ULLAH H.M.A., LEE E.J., KIM Y.D., CHUNG M.J., ELFADL A.K., PARK J.K., JEONG K.S. 2018. Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice. Vaccine. 63(3): 371–380, https:// doi: 10.1016/j.vaccine.2017.11.082.
HORIE K., HORIE N., ABDOU A.M., YANG J-O., YUN S-S., CHUN H-N., PARK C-K., KIM M., HATTA H. 2004. Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans. J Dairy Sci 87(12): 4073–4079. doi: 10.3168/jds.S0022-0302(04)73549-3.
HUSSAIN M., JABEEN N., RAZA F., SHABBIR S., BAIG A.A., AMANULLAH A., AZIZ B. 2020. Structural variations in human ACE2 may influence its binding with SARS‐CoV‐2 spike protein. J Med Virol 1-7. doi: 10.1002/jmv.25832.
HUSSEIN M.A, REHAN I.F., REHAN A.F, ELEIWA N.Z., ABDEL-RAHMAN M.A., FAHMY SG, AHMED A.S., YOUSSEF M., DIAB H.M., ALKAHTANI S.H., ABDEL-DAIM M.M., SHANAB O., AHMED E.K., HASSAN H., ELNAGAR A., ELKELISH A., HESHAM A., MAKY M.A. 2020. Egg yolk IgY: A novel trend of feed additives to limit drugs and to improve poultry meat quality. Front Vet Sci 145(7). doi: 10.3389/fvets.2020.00145.
IKEMORI Y., PERALTA R.C., KUROKI M., YOKOYAMA H., KODAMA Y. 1993. Research note: Avidity of chicken yolk antibodies to entero-toxigenic Escherichia coli fimbriae. Poult Sci 72(12): 2361‑2365. doi: 10.3382/ps.0722361.
IWAMOTO S., NISHIMICHI N., TATEISHI Y., SATO Y., HORIUCHI H., FURUSAWA S., SAWAMURA T., MATSUDA H. 2009. Generation and characterization of chicken monoclonal antibodies against human LOX-1, in: Mabs 1(4): 357–363. doi: 10.4161/mabs. 1.4.8919.x.
JANG S.H., CHOI S.Y., LEE Y.P., AN J.J., CHEONG H.G., KWON H.S., PARK J.K., BAEK D.Y. 2011. Composition for inhibiting hyperlipidemia and obesity by inhibiting intestinal absorption of cholesterol, PCT patent WO2011155705, https://patents.google.com/patent/WO2011155705A9/en?oq=WO2011155705.
JENSENIUS J.C., ANDERSEN I., HAU J., CRONE M., KOCH C. 1981. Eggs: Conveniently packaged antibodies. Methods for purification of yolk IgG. J Immunol Methods 46(1): 63‑68. doi: 10.1016/0022-1759(81)90333-1.
JONSSON A-K., LARSSON A., TÄNGDÉN T., MELHUS Å., LANNERGÅRD A. 2015. A trial with IgY chicken antibodies to eradicate faecal carriage of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases, Infect Ecol Epidemiol 5(1): 28224. doi: 10.3402/iee.v5.28224.
KATO M., HANYU Y. 2013. Construction of an scFv library by enzymatic assembly of VL and VH genes. J Immunol Meth 396(1–2): 15-22. doi: 10.1016/j.jim.2013.07.003.
KLEIN-SZANTO A.J.P, BASSI D. 2019. Keep recycling going: new approaches to reduce LDL-C. Biochem Pharmacol, doi: 10.1016/j.bcp.2019.04.003.
KODAMAN N., PAZOS A., SCHNEIDER B.G., PIAZUELO M.B., MERA R., SOBOTA R.S., SICINSCHI L.A., SHAFFER C.L., ROMERO-GALLO J., DE SABLET T., HARDER R.H., BRAVO L.E., PEEK JR.R.M., WILSON K.T., COVER T.L., WILLIAMS S.M., CORREA P. 2014. Human R.H. Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci 111(4): 1455–1460. doi: 10.1073/pnas.1318093111.
KOLLBERG H., CARLANDER D., OLESEN H., WEJÅKER P.E., JOHANNESSON M., LARSSON A. 2003. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 35(6): 433–440. doi: 10.1002/ppul.10290.
KOLLMORGEN G., PALME K., SEIDL A., SCHEIBLICH S., BIRZELE F., WILSON S., CLEMENS C., VOSS E., KAUFMANN M., HIRZEL K., RIEDER N., KRIPPENDORFF B.F., HERTING F., NIEDERFELLNER G. 2017. A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer. Sci Rep 7(1): 1–13. doi: 10.1038/s41598-017-17329-7.
KOVACS‑NOLAN J., MINE Y. 2012. Egg yolk antibodies for passive immunity. Annu Rev Food Sci Technol 3: 163‑182. doi: 10.1146/annurev-food-022811-101137.
KUMAR S., MAURYA V.K., PRASAD A.K., BHATT M.L., SAXENA S.K. 2020. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virusdis 31(1):1-9. doi: 10.1007/s13337-020-00571-5.
LEE W., SYED ATIF A., TAN S.C., LEOW C.H. 2017. Insights into the chicken IgY with emphasis on the generation and applications of chicken recombinant monoclonal antibodies. J Immunol Methods 447: 71‑85. doi: 10.1016/j.jim.2017.05.001.
LEIGHTON P.A., SCHUSSER B., YI H., GLANVILLE J., HARRIMAN W. 2015. A diverse repertoire of human immunoglobulin variable genes in a chicken B cell line is generated by both gene conversion and somatic hypermutation. Front Immunol 6:126. doi: 10.3389/fimmu.2015. 00126.
LEIVA C.L., CANGELOSI A., MARICONDA V., FARACE M., GEOGHEGAN P., BRERO L., FERNÁNDEZ-MIYAKAWA M.E., CHACANA P. 2019. IgY-based antivenom against Bothrops alternatus: production and neutralization efficacy, Toxicon 163: 84–92. doi: 10.1016/j.toxicon.2019.03.020.
LESLIE G.A., CLEM L.W. 1969. Phylogeny of immunoglobulin structure and function: immunoglobulins of the chicken, J. Exp. Med. 130 (6): 1337–1352. doi: 10.1084/jem.130.6.1337.
LETKO M., MARZI A., MUNSTER V. 2020. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5: 562–569. doi.10.1038/s41564-020-0688-y.
LI F. 2016. Structure, function, and evolution of coronavirus spike proteins. Ann Rev virol 2016; 3: 237-261. doi: 10.1146/annurev-virology-110615-042301.
LI X., WANG L., ZHEN Y., LI S., XU Y. 2015. Chicken egg yolk anti-bodies (IgY) as non‑ antibiotic production enhancers for use in swine production: A review. J Anim Sci Biotechnol 6(1): 40. doi: 10.1186/s40104-015-0038-8.
LIU L. 2015. Antibody glycosylation and its impact on the pharmaco-kinetics and pharmacodynamics of monoclonal antibodies and Fc‑fusion proteins. J Pharm Sci 104(6): 1866‑1884. doi: 10.1002/jps.24444.
LIU X.Y., POP L.M., SCHINDLER J., VITETTA E.S. 2012. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity. MAbs 4(1): 57–68. doi: 10.4161/ mabs.4.1.18348.
LUAN J., LU Y., JIN X., ZHANG L. 2020. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun 526(1):165-169. doi: 10.1016/j.bbrc.2020.03.047.
LUKASSEN S., CHUA R.L., TREFZER T., KAHN N.C., SCHNEIDER M.A., MULEY T., WINTER H., MEISTER M., VEITH C., BOOTS A.W., HENNIG B.P., KREUTER M., CONRAD C., EILS R. 2020. SARS‐CoV‐2 receptor ACE 2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J 39(10) : e105114. doi: 10.15252/embj.20105114.
MA S., ZHANG Y. 2011. Neutralization effects of egg yolk immunoglobulin (IgY) and Fab’ fragment against lipopolysaccharide (LPS) in burned mice model. African J Biotechnol 10(29): 5677–5682. doi: 10.5897/AJB10.1370.
MAIL ONLINE. 2020. FDA approves first US coronavirus treatment: Doctors across the US can now treat the sickest Americans with plasma from recovered patients. https://www.dailymail.co.uk/ health/article -8147631/Can-blood-coronavirus-survivors-treat-newly-ill.html. Accessed March 24, https://www.dailymail.co.uk/health/article-8147631/Can-blood-coronavirus-survivors-treat-newly-ill.html
MAITI P.K. 2015. Polyclonal antibodies against Clostridium difficile and uses thereof, European patent EP2957570, https://patents.google.com/patent/EP2957570A1/en?oq=EP2957570.
MANSOUR N.M., GROTH S.S., ANANDASABAPATHY S. 2016. Esophageal adenocarcinoma: screening, surveillance, and management. Annu Rev Med 68: 213–227. doi: 10.1146/annurev-med-050715-104218.
MCCASKILL J.L., RESSEL S., ALBER A., REDFORD J., POWER U.F., SCHWARZE J., DUTIA B.M., BUCK A.H. 2017. Broad‑spectrum inhibition of respiratory virus infection by MicroRNA mimics targeting p38 MAPK signaling. Mol Ther Nucleic Acids 27(14): 256‑266. doi: 10.1016/j.omtn.2017.03.008.
MERESSE B., MALAMUT G., CERF-BENSUSSAN N. 2012. Celiac disease: an immunological jigsaw. Immunity 36(6): 907–919. doi: 10.1016/j.immuni.2012.06.006.
MITTENESS B., PHILLIPS C. 2013. Compositions against bacterial toxins, PCT patent WO2013009843, https://patents.google.com/patent/WO2013009843A1/nl.
MOGAYZEL P.J.JR., NAURECKAS E.T., ROBINSON K.A., BRADY C., GUILL M., LAHIRI T., LUBSCH L., MATSUI J., OERMANN C.M., RATJEN F., ROSENFELD M., SIMON R.H., HAZLE L., SABADOSA K., MARSHALL B. 2014. Cystic fibrosis foundation pulmonary clinical practice guidelines committee: cystic fibrosis foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc 11(10): 1640‑1650. doi: 10.1513/AnnalsATS.201404-166OC.
MOGAYZEL P.J.JR., NAURECKAS E.T., ROBINSON K.A., MUELLER G., HADJILIADIS D., HOAG J.B., LUBSCH L., HAZLE L., SABADOSA K., MARSHALL B. 2013. Pulmonary clinical practice guidelines committee: Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187(7): 680‑689. doi: 10.1164/rccm.201207-1160OE.
MONY T.J., KWON H-S., WON, M-K., KANG Y-M., LEE S-H., KIM S-Y., BAEK D-Y., ELAHI F. 2019. Anti-urease immunoglobulin (IgY) from egg yolk prevents Helicobacter pylori infection in a mouse model. Food Agric Immunol 30(1): 662–676. doi: 10.1080/09540105.2019.1617251.
MUDILI V., MAKAM S.S., SUNDARARAJ N., SIDDAIAH C., GUPTA V.K., RAO L.P.V. 2015. A novel IgY-Aptamer hybrid system for cost-effective detection of SEB and its evaluation on food and clinical samples, Nat Publ Gr 5: 1–12. doi: 10.1038/srep15151.
MULLER S., SCHUBERT A., ZAJAC J., DYCK T., OELKRUG C. 2015. IgY anti-bodies in human nutrition for disease prevention. Nutr J 14(1): 109. doi: 10.1186/s12937-015-0067-3.
MUNTEANU A.N., SURCEL M., CONSTANTIN C., NEAGU M. 2019. Syncytial virus respiratory infections in children ‑ immunological aspects. Rev Biol Biomed Sci 2: 29‑39. doi: 10.31178/rbbs.2019.2.1.4.
MURPHY K. 2012. Structural variation in immunoglobulin constant regions, Janewaýs Immunobiol, eighth ed., Garland Science, New York, 175. https://www.ncbi.nlm.nih.gov/books/NBK27106/.
MWALE P.F., LEE C-H., LIN L-T., LEU S-J., HUANG Y-J., CHIANG L-C., MAO Y-C., YANG Y-Y. 2020. Expression, purification, and characterization of anti-Zika virus envelope protein: polyclonal and chicken-derived single chain variable fragment antibodies. Int J Mol Sci 21(2): 492. doi: 10.3390/ijms21020492.
NEHER R.A., DYRDAK R., DRUELLE V., HODCROFT E.B., ALBERT J. 2020. Impact of seasonal forcing on a potential SARS-CoV-2 pandemic. MedRxiv, doi:10.1101/2020.02.13.20022806.
NERI P., TOKORO S., KOBAYASHI R., SUGIYAMA T., UMEDA K., SHIMIZU T., TSUJI T., KODAMA Y., OGUMA K., MORI H. 2011. Specific egg yolk immunoglobulin as a new preventive approach for shiga-toxin-mediated diseases. PLoS One 6(10). doi: 10.1371/journal.,pone.0026526.
NGUYEN H.H., TUMPEY T.M., PARK H.J., BYUN Y‑H., TRAN L.D., NGUYEN V.D., KILGORE P.E., CZERKINSKY C., KATZ J.M., SEONG B.L., SONG G.M., KIM Y.B., DO H.T., NGUYEN T., NGUYEN C. 2010. Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice. PLoS One 5(4): e10152. doi: 10.1371/journal.,pone.0010152.
NILSSON E., KOLLBERG H., JOHANNESSON M., WEJÅKER P-E., CARLANDER D., LARSSON A. 2007. More than 10 Years’ continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. J Med Food 10(2): 375–378. doi: 10.1089/jmf.2006.214.
NILSSON E., LARSSON A. 2005. Chicken anti-protein L for the detection of small amounts of protein L in the presence of IgG, Hybridoma (Larchmt) 24. doi: 10.1089/hyb.2005; 24(2): 112-114.
NISHIBORI N., HORIUCHI H., FURUSAWA S., MATSUDA H. 2006. Humanization of chicken monoclonal antibody using phage-display system. Mol Immunol 43(6): 634–642. doi: 10.1016/j.molimm.2005.04.002.
OTTERBECK A., HANSLIN K., LIDBERG LANTZ E., LARSSON A., STÅLBERG J., LIPCSEY M. 2019. Inhalation of specific anti-Pseudomonas aeruginosa IgY antibodies transiently decreases P. aeruginosa colonization of the airway in mechanically ventilated piglets. Intensive Care Med Exp. 7(1): 1–10. doi: 10.1186/s40635-019-0246-1.
PANSRI P., JARUSERANEE N., RANGNOI K., KRISTENSEN P., YAMABHAI M. 2009. A compact phage display human scFv library for selection of antibodies to a wide variety of antigens. BMC Biotechnol 2009; 9(1): 6. doi: 10.1186/1472-6750-9-6.
PARMA Y.R., CHACANA P., ROGÉ A., KAHL A., CANGELOSI A., GEOGHEGAN P., LUCCHESI P.M.A., FERNÁNDEZ-MIYAKAWA M.E. 2011. Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy, Toxicon 58(4): 380–388. doi: 10.1016/j.toxicon.2011.07.009.
PASKI S., NERO T.M., TOBACK F.G., BOONE D.L. 2015. Mo1806 gastrokine- 1: a gastric protein that protects mice against experimental colitis. Gastroenterology 142(5): S-689. doi: 10.1016/s0016-5085(12)62659-6.
PASTEUR M.C., BILTON D., HILL A.T. 2010. British Thoracic Society Bronchiectasis non ‑CF Guideline Group: British Thoracic Society guideline for non‑CF bronchiectasis. Thorax 65(1): 1-58. doi: 10.1136/thx.2010.136119.
PATTERSON R., YOUNGNER J.S., WEIGLE W.O., DIXON F.J. 1962. The metabolism of serum proteins in the hen and chick and secretion of serum proteins by the ovary of the hen. J Gen Physiol 45(3): 501-513. doi: 10.1085/jgp.45.3.501.
PAULY D., CHACANA P.A., CALZADO E.G., BREMBS B., SCHADE R. 2011. IgY technology: Extraction of chicken antibodies from egg yolk by polyethylene glycol (PEG) precipitation. J Vis Exp 3084. doi: 10.3791/3084.
PEREIRA E., VAN TILBURG M., FLOREAN E., GUEDES M. 2019. Egg yolk antibodies (IgY) and their applications in human and veterinary health: a review, Int. Immunopharmacol 73: 293–303. doi: 10.1016/j.intimp.2019.05.015.
PERLMAN S., NETLAND J. 2009. Coronaviruses post‑SARS: Update on replication and pathogenesis. Nat Rev Microbiol 7(6): 439‑450. doi: 10.1038/nrmicro2147.
PERLMAN S., NETLAND J. 2009. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 7(6):439–50. doi: 10.1038/nrmicro2147.
PINEDA OLVERA B., RANGEL LÓPEZ E., PÉREZ-DE LA CRUZ V., HERNÁNDEZ PEDRO N.Y. 2015. Production of the immunotoxin igy anti CD133 coupled to an abrin for treating tumors in the central nervous system and/or neoplasms related to carcinogenic stem cells, Mexico patent MX2015004554, https://patents.google.com/patent/MX2015004554A/en?oq=MX2015004554.
QAZI S., ABOUBAKER S., MACLEAN R., FONTAINE O., MANTEL C., GOODMAN T., YOUNG M., HENDERSON P., CHERIAN T. 2015. Ending preventable child deaths from pneumonia and diarrhoea by 2025. Development of the integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea. Arch Dis Child 100(1): 23-28. doi:10.1136/archdischild-2013-305429.
RAHMAN S., HIGO‑MORIGUCHI K., HTUN K.W., TANIGUCHI K., ICATLO F.C.JR., TSUJI T., KODAMA Y., VAN NGUYEN S., UMEDA K., OO HN., MYINT Y.Y., HTUT T., MYINT S.S., THU H.M., FATMAWI N.N.D., OGUMA K. 2012. Randomized placebo‑controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus‑associated diarrhea among pediatric patients. Vaccine 30(31): 4661‑4669. doi: 10.1016/j.vaccine.2012.04.091.
RAHMANA S., VAN NGUYEN S., ICATLO F.C.JR., UMEDA K., KODAMA Y. 2013. Oral passive IgY‑based immunotherapeutics: A novel solution for prevention and treatment of alimentary tract diseases. Hum Vaccin Immunother 9(5): 1039‑1048. doi: 10.4161/hv.23383.
RAHMANB S., UMEDA K., ICATLO F.C., LEE K.W., KIM S.H., CHOI H.J., HAN B.K., PARK Y.S., NGUYEN V.S. 2013. In vitro cytoprotective effect of infant milk formula for-tified with human rotavirus-specific hyperimmune yolk immunoglobulins (IgY). Food Sci Biotechnol 22(6): 1699–1705. doi: 10.1007/s10068-013-0269-4.
RAJIC A., STEHMANN C., AUTELITANO D.J., VRKIC A.K., HOSKING C.G., RICE G.E., ILAG L.L. 2009. Protein depletion using IgY from chickens immunised with human protein cocktails. Prep Biochem Biotechnol 39(3): 221‑247. doi: 10.1080/10826060902952915.
RANJBAR M., BEHROUZ B., NOROUZI F., MOUSAVI GARGARI S.L. 2019. Anti‑PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models. Mol Immunol 116: 98‑105. doi: 10.1016/j.molimm.2019.10.005.
REDONDO L.M., REDONDO E.A., DAILOFF G.C., LEIVA C.L., DÍAZ-CARRASCO J.M., BRUZZONE O.A., CANGELOSI A., GEOGHEGAN P., FERNANDEZ-MIYAKAWA M.E. 2017. EFFECTS of Clostridium perfringens iota toxin in the small intestine of mice. Anaerobe 48. doi: 10.1016/j.anaerobe. 2017.07.007.
REHAN I., MOHAMMED H., FAHMY S., ELNAGAR A., YOUSSEF M., AND SHANAB O. 2019. Influence of photoperiod and circulating-IgY on some behavioural patterns of chicks during the first week of life. IJVSAH 4(2): 18-25. ISSN Number: 2456-2912.
REHAN I.F., YOUSSEF M., ABDEL-RAHMAN M.A.M., FAHMY S.G., AHMED E., AHMED A.S., MAKY M.A., DIAB H.M., SHANAB O., ALKAHTANI S., ABDEL-DAIM M.M., HASSAN H., REHAN AF., HUSSIEN M.A., ELEIWA N.Z., ELNAGAR A., ABDEEN A., HESHAM A. 2020. The impact of probiotics and egg yolk IgY on behavior and blood parameters in a broiler immune stress Model. Front Vet Sci 145(7): 1-8. doi: 10.3389/fvets.2020.00145.
REHMAN S.U., SHAFIQUE L., IHSAN A., LIU Q. 2020. Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2. Pathogens 9(3):240. doi: 10.3390/pathogens9030240.
RITZ B.W., ALEXANDER G.M., NOGUSA S., PERREAULT M.J., PETERLIN B.L., GROTHUSEN J.R., SCHWARTZMAN R.J. 2011. Elevated blood levels of inflammatory monocytes (CD14+CD16+) in patients with complex regional pain syndrome. Clin Exp Immunol 164(1): 108–117. doi: 10.1111/j.1365-2249.2010. 04308.x.
ROSE M.E., ORLANS E., BUTTRESS N. 1974. Immunoglobulin classes in the hen's egg: Their segregation in yolk and white. Eur J Immunol 4(7): 521‑523. doi: 10.1002/eji.1830040715.
ROTA P.A., OBERSTE M.S., MONROE S.S., NIX W.A., CAMPAGNOLI R., ICENOGLE J.P., PEÑARANDA S., BANKAMP B., MAHER K., CHEN M.H., TONG S., TAMIN A., LOWE L., FRACE M., DERISI J.L., CHEN Q., WANG D., ERDMAN D.D., PERET T.C.T, BURNS C., KSIAZEK T.G., ROLLIN P.E., SANCHEZ A., LIFFICK S., HOLLOWAY B., LIMOR J., MCCAUSTLAND K., OLSEN-RASMUSSEN M., FOUCHIER R., GÜNTHER S., OSTERHAUS A.D.M.E., DROSTEN C., PALLANSCH M.A., ANDERSON L.J., BELLINI W.J. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Sci 300(5624): 1394‑1399. doi: 10.1126/science.1085952.
SAMPLE D.A., SUNWOO H.H., HUYNH H.Q., RYLANCE H.L., ROBERT C.L., XU B.W., KANG S.H., GUJRAL N., DIELEMAN L.A. 2017. IgY, a novel egg yolk-derived anti-gliadin antibody, is safe for patients with celiac disease. Dig Dis Sci 62(5): 1277–1285. doi: 10.1007/s10620-016-4426-5.
SAPKOTA A. 2020. Transmission, pathogenesis, replication of SARS-CoV-2 (COVID-19). Microbe Notes, https://microbenotes.com/transmission-pathogenesis-replication-of-sars-cov-2/.
SCAMELL A.W. 2013. Uses of antibodies, United States patent US20130295109, https://patents.google.com/patent/US20130295109A1/en?oq=US20130295109.
SCHADE R., CALZADO E.G., SARMIENTO R., CHACANA P., PORANKIEWICZ-ASPLUND J., TERZOLO H. 2005. Chicken egg yolk antibodies (IgY-technology): a review of progress in production and use in research and human and veterinary medicine, Altern Lab Anim 33(2): 129–154. doi: 10.1177/026119290503300208.
SCHMITZ U., VERSMOLD A., KAUFMANN P., FRANK H-G. 2000. Phage display: a molecular tool for the generation of antibodies—a Review. Placenta 21:106–112. doi: 10.1053/plac.1999.0511.
SCHULLER Y., BIEGSTRAATEN M., HOLLAK C.E.M., KLÜMPEN H.J., GISPEN DE WIED C.C., STOYANOVA BENINSKA V. 2018. Oncologic orphan drugs approved in the EU - Do clinical trial data correspond with real-world effectiveness? Orphanet J Rare Dis 13(1): 1–11. doi: 10.1186/s13023-018-0900-9.
SCHUSSER B., YI H., COLLARINI E.J., IZQUIERDO S.M., HARRIMAN W.D., ETCHES R.J., LEIGHTON P.A. 2013. Harnessing gene conversion in chicken B cells to create a human antibody sequence repertoire. PLoS One 8(11): e80108. doi: 10.1371/journal.,pone.0080108.
SCHUSTER A., BEND J. 2018. Impact PsAer-IgY Final Study Report - EudraCT Number: 2011-000801-39. https://www.clinicaltrialsregister.eu/ctr-search/rest/ download/result/attachment/2011-000801-39/1/24990, (accessed 16 Jul 2019).
SESARMAN A., MIHAI S., CHIRIAC M.T., OLARU F., SITARU A.G., THURMAN J.M., ZILLIKENS D., SITARU C. 2008. Binding of avian IgY to type VII collagen does not activate complement and leucocytes and fails to induce subepidermal blistering in mice. Br J Dermatol 158(3): 463–471. doi: 10.1111/j.1365-2133.2007. 08388.x.
SHARMA J.M. 1999. Introduction to poultry vaccines and immunity. Adv Vet Med 41: 481‑494. doi: 10.1016/s0065-3519(99)80036-6.
SHEAHAN T., ROCKX B., DONALDSON E., SIMS A., PICKLES R., CORTI D., BARIC R. 2008. Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. J Virol 82(5):2274-2285. doi: 10.1128/JVI.02041-07.
SHEN C., WANG Z., ZHAO F., YANG Y., LI J., YUAN J., WANG F., LI D., YANG M., XING L., WEI J., XIAO H., YANG Y., QU J., QING L., CHEN L., XU Z., PENG L., LI Y., ZHENG H., CHEN F., HUANG K., JIANG Y., LIU D., ZHANG Z., LIU Y., LIU L. 2020. Treatment of 5 critically ill patients with COVID‑19 with convalescent plasma. JAMA 323(16): 1582-1589, (Epub ahead of print). doi: 10.1001/jama.2020.4783.
SHENG B., CHANǴAN W., TIANFU C., NA W., HAIWEI B. 2014. Preparation method and preparation agent of nano lipidosome compound IgY resisting Helicobacter pylori, Pylori bacteria as well as related enzymes and adhesin of Helicobacter pylori and Pylori bacteria, China patent CN103961704, https://patents.google.com/patent/CN103961704A/en.
SHIMAMOTO C., TOKIOKA S., HIRATA I., TANI H., OHISHI H., KATSU K.I. 2002. Inhibition of Helicobacter pylori infection by orally administered yolk-derived anti-Helicobacter pylori antibody, Hepatogastroenterology 49(45): 709–714. https://pubmed.ncbi.nlm.nih.gov/12063975/.
SKRINER K. 2013. IgY composition for use in coeliac disease, PCT patent WO2013045469, https://patents.google.com/patent/WO2013045469A1/en?oq=WO2013045469.
SOMASUNDARAM R., CHORARIA A., ANTONYSAMY M. 2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review. Int Immunopharmacol 85: 106654. doi: 10.1016/j.intimp.2020.106654.
SPARROW E., FRIEDE M., SHEIKH M., TORVALDSEN S. 2017. Therapeutic antibodies for infectious diseases. Bull World Health Organ 95(3): 235‑237. doi: 10.2471/BLT.16.178061.
SPILLNER E., BRAREN I., GREUNKE K., SEISMANN H., BLANK S., DU PLESSIS D. 2012. Avian IgY antibodies and their recombinant equivalents in research, diagnostics and therapy. Biologicals 40(5): 313‑322. doi: 10.1016/j.biologicals.2012.05.003.
SPROTTE G., WAAGA-GASSER A.M. 2016. Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment, PCT patent WO2016166246, https://patents.google.com/patent/WO2016166246A1/en?oq=WO2016166246.
STADLMANN V., HARANT H., KORSCHINECK I., HERMANN M., FORSTER F., MISSBICHLER A. 2015. Novel avian single-chain fragment variable (scFv) targets dietary gluten and related natural grain prolamins, toxic entities of celiac disease. BMC Biotechnol 15(109): 1–14. doi: 10.1186/s12896-015-0223-z.
STARZL T. 2012. Compositions and methods for treatment in broad-spectrum, un-differentiated or mixed clinical applications, PCT patent WO2012071346, https://patents.google.com/patent/WO2012071346A1/en.
STEPHENSON S-A., DOUGLAS E.L., MERTENS-WALKER I., LISLE J.E., MAHARAJ M.S., HERINGTON A.C. 2015. Anti-tumour effects of antibodies targeting the extracellular cy-steine-rich region of the receptor tyrosine kinase EphB4. Oncotarget 6(10): 7554. doi: 10.18632/oncotarget.3199.
SUN K., GU L., MA L., DUAN Y. 2020. Atlas of ACE2 gene expression in mammals reveals novel insights in transmission of SARS-Cov-2. BioRxiv, doi: 10.1101/2020.03.30.015644.
SUN S., MO W., JI Y., LIU S. 2001. Preparation and mass spectrometric study of egg yolk antibody (IgY) against rabies virus, Rapid Commun. Mass Spectrom. 15(9): 708–712. doi: 10.1002/rcm.271.
SUTTON B.J. 1989. Immunoglobulin structure and function: The interaction between antibody and antigen. Curr Opin Immunol 2(1): 106–113. doi: 10. 1016/0952-7915(89)90105-2.
SUZUKI H., NOMURA S., MASAOKA T., GOSHIMA H., KAMATA N., KODAMA Y., ISHII H., KITAJIMA M., NOMOTO K., HIBI T. 2004. Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther 20 (1): 185–192. doi: 10.1111/j.1365-2036.2004.02027.x.
TAI W., HE L., ZHANG X., PU J., VORONIN D., JIANG S., ZHOU Y., DU L. 2020. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 17(6):613-620. doi: 10.1038/s41423-020-0400-4.
TAYLOR A.I., BEAVIL R.L., SUTTON B.J., CALVERT R.A. 2009. A monomeric chicken IgY receptor binds IgY with 2: 1 stoichiometry. J Biol Chem 284(36): 24168–24175. doi: 10.1074/jbc.M109.020263.
TAYLOR A.I., SUTTON B.J., CALVERT R.A. 2010. Mutations in an avian IgYFc fragment reveal the locations of monocyte Fc receptor binding sites. Develop Comp Immunol 34(2): 97–101. doi: 10.1016/j.dci.2009.08. 012.
THIRUMALAI D., VISAGA AMBI S., VIEIRA-PIRES R.S., ZHANG X., SEKARAN S., KRISHNAN U. 2019. Chicken egg yolk antibody (IgY) as diagnostics and therapeutics in parasitic infections – a review, Int. J. Biol. Macromol. 136: 755–763. doi:10.1016/j.ijbiomac.2019.06.118.
THOMSEN K., CHRISTOPHERSEN L., BJARNSHOLT T., JENSEN P., MOSER C., HØIBY N. 2015. Anti-Pseudomonas aeruginosa IgY antibodies induce specific bacterial aggregation and internalization in human polymorphonuclear neutrophils. Infect Immun 83(7): 686–2693. doi: 10.1128/IAI.02970-14.
THOMSEN K., CHRISTOPHERSEN L., BJARNSHOLT T., JENSEN P.O., MOSER C., HØIBY N. 2016. Anti‑Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model. J Cyst Fibros 15(2): 171‑178. doi: 10.1016/j.jcf.2015.08.002.
THOMSEN K., CHRISTOPHERSEN L., JENSEN PØ., BJARNSHOLT T., MOSER C., HØIBY N. 2016. Anti‑Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils. Hum Vaccin Immunother 12(7): 1690‑1699. doi: 10.1080/21645515.2016.1145848.
THU H.M., MYAT T.W., WIN M.M., THANT K.Z., RAHMAN S., UMEDA K., NGUYEN SV., ICATLO F.C.JR., HIGO‑MORIGUCHI K., TANIGUCHI K., TSUJI T., OGUMA K., KIM S.J., BAE H.S., CHOI H.J. 2017. Chicken egg yolk antibodies (IgY) for prophylaxis and treatment of rotavirus diarrhea in human and animal neonates: A concise review. Han ‑gug Chugsan Sigpum Hag‑hoeji 37(1): 1‑9. doi: 10.5851/kosfa.2017.37.1.1.
TORCHÉ A.M., LE DIMNA M., LE CORRE P., MESPLÈDE A., LE GAL S., CARIOLET R., LE POTIER M.F. 2006. Immune responses after local administration of IgY loaded‑ PLGA microspheres in gut‑asso-ciated lymphoid tissue in pigs. Vet Immunol Immunopathol 109(3-4): 209‑217. doi: 10.1016/j.vetimm.2005.08.016.
TSITOURA E., BIBAKI E., BOLAKI M., VASARMIDI E., TRACHALAKI A., SYMVOULAKIS E.K., SPANDIDOS D.A., ANTONIOU K.M. 2020. (Comment) Treatment strategies to fight the new coronavirus SARS‑CoV‑2: A challenge for a Rubik's Cube solver. Exp Ther Med 20(1): 147-150. doi: 10.3892/etm.2020.8692.
TSUKAMOTO Y. 2013. Antibody and antibody-containing composition, PCT patent WO2013027356, https://patents.google.com/patent/WO2013027356A1/en?oq=WO2013027356.
TSURUSHITA N., PARK M., PAKABUNTO K., ONG K., AVDALOVIC A., FU H., JIA A., VÁSQUEZ M., KUMAR S. 2004. Humanization of a chicken anti-IL-12 monoclonal antibody, J Immunol Meth 295(1–2): 9–19. doi: 10.1016/j.jim.2004.08.018.
VEGA C.G., BOK M., VLASOVA A.N., CHATTHA K.S., FERNÁNDEZ F.M., WIGDOROVITZ A., PARREÑO V.G., SAIF L.J., SALMON H. 2012. IgY anti-bodies protect against human Rotavirus induced diarrhea in the neonatal gnotobiotic piglet disease model. PLoS One 7(8): e42788. doi: 10.1371/journal.,pone.0042788.
WAHBA L., JAIN N., FIRE A.Z., SHOURA M.J., ARTILES K.L., MCCOY M.J., JEONG D-E. 2020. An extensive meta-metagenomic search identifies SARS-CoV-2-homologous sequences in pangolin lung virome. Nat 5(3):e00160-20. doi: 10.1038/s41586-020-2008-3.
WALLS A.C., PARK Y.J., TORTORICI M.A., WALL A., MCGUIRE A.T., VEESLER D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.Cell 181(2): 281-292. doi: 10.1101/2020.02.19.956581.
WAN Y., SHANG J., GRAHAM R., BARIC R.S., LI F. 2020. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. J Virol 94(7): e00127-20. doi:10.1128/JVI.00127-20.
WAN Y., SHANG J., GRAHAM R., BARIC R.S., LI FJ. 2020. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Coronavirus. Virol 94(7):e00127-20. doi: 10.1128/JVI.00127-20.
WARR G.W., MAGOR K.E., HIGGINS D.A. 1995. IgY: clues to the origins of modern anti-bodies. Immunol Today 16(8): 392–398. doi: 10.1016/0167-5699(95)80008-5.
WATANABE Y., BOWDEN T.A., WILSON I.A., CRISPIN M. 2019. Exploitation of glycosylation in enveloped virus pathobiology. BBA- Gen Subj 1863(10): 1480-1497. doi: 10.1016/j.bbagen.2019.05.012.
WEI S., YIQIANG A., QING G. 2017. Preparation method of egg yolk antibody containing Helicobacter pylori resisting IgY and application, China patent CN106632672, https://patents.google.com/patent/CN106632672A/en?oq=CN106632672.
WEIDINGER S., NOVAK N. 2016. Atopic dermatitis. Lancet 387(10023): 1109–1122. doi: 10.1007/978-3-642-02035-3_20.
WELTZIN R., MONATH T.P. 1999. Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev 1999; 12(3): 383‑393. doi: 10.1128/CMR.12.3.383.
WESJOHANN JAN, SPROTTE G., WAAGA-GASSER A.M. 2012. Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists, PCT patent WO2012136534, https://patents.google.com/patent/WO2012136534A2/en?oq=WO2012136534.
WRAPP D., WANG N., CORBETT K.S., GOLDSMITH J.A., HSIEH C-L., ABIONA O., GRAHAM B.S., MCLELLAN JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Sci 2020; 367(6483): 1260-1263.doi:10.1126/science.abb2507.
WU L., OFICJALSKA K., LAMBERT M., FENNELL B.J., DARMANIN-SHEEHAN A., SHÚILLEABHÁIN D.N., AUTIN B., CUMMINS E., TCHISTIAKOVA L., BLOOM L., PAULSEN J., GILL D., CUNNINGHAM O., FINLAY W.J.J. 2012. Fundamental characteristics of the immunoglobulin VH repertoire of chickens in comparison with those of humans, mice, and camelids. J Immunol 188(1): 322–333. doi: 10.4049/jimmunol.1102466.
XIAO Y., GAO X., TARATULA O., TREADO S., URBAS A., HOLBROOK R.D., CAVICCHI R.E., AVEDISIAN C.T., MITRA S., SAVLA R., WAGNER P.D., SRIVASTAVA S., HE H. 2009. Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells. BMC Cancer 9(1): 351. doi: 10.1186/1471-2407-9-351.
XIE Y-M., GAO S., WANG L-Y., WANG Z-L. 2013. Therapeutic effect of probiotics and oral IgY as supplementary drugs in the treatment of pediatric rotavirus enteritis: a comparative study. Chinese J Contemp Pediatr 15(11): 1000–1005. doi: 10.7499/j.issn.1008-8830.2013.11.018.
XU Y., LI X., JIN L., ZHEN Y., LU Y., LI S., YOU J., WANG L. 2011. Application of chicken egg yolk immunoglobulins in the control of terrestrial and aquatic animal diseases: A review. Biotechnol Adv 29(6): 860‑ 868. doi: 10.1016/j.biotechadv.2011.07.003.
YOON A., SHIN J.W., KIM S., KIM H., CHUNG J. 2016. Chicken scFvs with an artificial cysteine for site-directed conjugation. PloS one 11(1):1-12-. doi: 10.1371%2Fjournal.,pone.0146907.
YOU Z., YANG H., XIN W., KANG L., GAO S., WANG J., ZHANG T., WANG J. 2014. Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models, Hum. Vaccines Immunother. 10(8): 2321–2327. doi: 10. 4161/hv.29433.
ZHANG X., CALVERT R.A., SUTTON B.J., DORÉ K.A. 2017. IgY: a key isotype in antibody evolution. Biol Rev 92(4): 2144–2156. doi: 10.1111/brv.12325.
ZHEN Y.H., JIN L.J., LI X.Y., GUO J., LI Z., ZHANG B.J., FANG R., XU Y.P. 2009. Efficacy of specific egg yolk immunoglobulin (IgY) to bovine mastitis caused by Staphylococcus aureus. Vet Microbiol 133(4): 317–322. doi: 10. 1016/j.vetmic.2008.07.016.
ZHOU P., YANG X-L., WANG X-G., HU B., ZHANG L., ZHANG W., SI H-R., ZHU Y., LI B., HUANG C-L., CHEN H-D., CHEN J., LUO Y., GUO H., JIANG R-D., LIU M-Q., CHEN Y., SHEN X-R., WANG X., ZHENG X-S., ZHAO K., CHEN Q-J., DENG F., LIU L-L., YAN B., ZHAN F-X., WANG Y-Y., XIAO G-F., SHI Z-L. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nat 579(7798): 270–273. doi:10.1038/s41586-020-2012-7.
ZHOU X., MA S. 2018. Anti-lipopolysaccharide egg yolk antibodies enhance the phagocytosis of mammalian phagocytes. Biol Open 2018: 7(6). doi: 10.1242/ bio.032821.
ZHOU X., WANG P., CHEN Y., MA S. 2018. Intact anti-LPS IgY is found in the blood after intragastric administration in mice. FEBS Open Bio 9(3): 428–436. doi: 10.1002/2211-5463.12571.
ZHOU X., WANG Y., AHN D.U., CAI Z. 2020. An easy and simple separation method for Fc and Fab fragments from chicken immunoglobulin Y (IgY). J Chromatogr B Analyt Technol Biomed Life Sci 1141: 122011. doi: 10.1016/j.jchromb.2020.122011. | ||||
Statistics Article View: 2,583 PDF Download: 947 |
||||